Skip to main content
. Author manuscript; available in PMC: 2020 May 27.
Published in final edited form as: Pharm Res. 2018 Aug 21;35(10):194. doi: 10.1007/s11095-018-2473-7

Table 4:

Comparison of mean (SD) in vitro aerosol drug delivery using steady state performance and realistic inhalation conditions with the revised delivery system and Cannula 2. Values are reported as a percentage of nominal dose loaded into the capsule. Standard deviations (SD) shown in parenthesis [n=3].

Description Steady State Deep Nasal Passive Nasal
Capsule (%) 8.6 (0.5) 11.1 (2.6) 9.5 (2.5)
Device (%) 1.6 (0.4) 1.7 (0.4) 1.7 (0.6)
Device ED (%) 89.8 (0.2) 87.2 (2.9) 88.8 (2.9)
Spacer (%) 6.4 (0.8) 7.4 (2.2) 7.3 (1.6)
Y Retention (%) 0.5 (0.1) 0.7 (0.3) 0.7 (0.3)
Tubing Retention (%) 4.0 (0.8) 5.0 (1.8) 4.9 (1.4)
Cannula Retention (%) 4.1 (1.2) 4.7 (1.9) 4.6 (1.5)
Cannula ED (%) 74.7 (3.0) 69.3 (4.2) 71.4 (1.9)
NMT (%) 6.9 (2.0) 8.9 (3.1) 6.2 (2.1)
Filter Delivery (%) 61.6 (4.8) 53.4 (6.2) 55.3 (4.1)
Recovery (%)* 93.8 (0.7) 92.9 (1.2) 90.2 (0.3)**
*

p<0.05 significant effect of system design on Recovery (one-way ANOVA).

**

p<0.05 significant difference compared to Steady State (post-hoc Tukey).